title: Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
abstract: The fifth "Melanoma Bridge Meeting" took place in Naples, December 1-5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient's clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.
authors.affiliation: Laboratory of Integrative Cancer Immunology, INSERM UMRS1138 Cordeliers Research Center, University Pierre et Marie Curie, Paris 6, 15 Rue de l'Ecole de Medecine, 75006, Paris, France.|University Paris Descartes, 45 Rue Saints Pères, 75006, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Galon
authors.affiliation: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, 97213, USA.|Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, 97239, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Fox
authors.affiliation: Department of Pathology, Providence Portland Medical Center, Portland, OR, 97213, USA.
authors.forename: C B
authors.initials: CB
authors.lastname: Bifulco
authors.affiliation: Department of Oncology-Pathology, The Karolinska Hospital, Stockholm, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Masucci
authors.affiliation: Institute of Pathology, University of Bern, Bern, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Rau
authors.affiliation: Unit of Pathology, IRCCS, Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Botti
authors.affiliation: Sidra Medical and Research Center, Doha, Qatar.
authors.forename: F M
authors.initials: FM
authors.lastname: Marincola
authors.affiliation: IRCCS, Istituto Nazionale Tumori, Fondazione "G. Pascale",Scentific Directorate, Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ciliberto
authors.affiliation: University Paris Descartes, 45 Rue Saints Pères, 75006, Paris, France.|Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l'Ecole de Medecine, 75006, Paris, France.|Centre de Recherche des Cordeliers, University Pierre et Marie Curie, Paris 6, 15 Rue de l'Ecole de Medecine, 75006, Paris, France.|Immunomonitoring Platform, Laboratory of Immunology, Georges Pompidou European Hospital, 20-40 Rue Leblanc, 75015, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Pages
authors.affiliation: Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy.
authors.forename: P A
authors.initials: PA
authors.lastname: Ascierto
authors.affiliation: Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy. marilenacapone@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Capone
mesh_terms: D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000276:immunology*
keywords: Immunoprofiling; Immunoscore; Melanoma